HpVac is focused on the development of GBC-R1 as a preventive and therapeutic first-line therapy against asthma, eczema, food allergies and related allergic diseases, as well as inflammatory bowel conditions such as Crohn's disease and ulcerative colitis.
HpVac holds an exclusive, world-wide licence from the University of Zurich.
